Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Apr
5
2017
New York AG Takes Enforcement Action Against Heart Monitoring Apps: Murmurs of Concern are Heard in mHealth App World Sheppard, Mullin, Richter & Hampton LLP
Mar
19
2024
Time to Refresh? FDA Issues Draft Guidance on Key Information and Informed Consent Sheppard, Mullin, Richter & Hampton LLP
Jul
26
2010
Has the Time Come for "Total Recall" of Medical Products? Sheppard, Mullin, Richter & Hampton LLP
Jan
6
2011
Landmark Greenhouse Gas Cap-and-Trade Program Adopted in California Sheppard, Mullin, Richter & Hampton LLP
Oct
6
2011
California AB 32's Cap-And-Trade Program Developments Sheppard, Mullin, Richter & Hampton LLP
Jan
11
2022
Day One Notes for the 40th Annual J.P. Morgan Healthcare Conference, 2022 Sheppard, Mullin, Richter & Hampton LLP
Oct
5
2022
Takeaways From the U.S. Patent and Trademark Office’s Artificial Intelligence and Emerging Technologies Partnership Series – Part Two of Three Sheppard, Mullin, Richter & Hampton LLP
Oct
12
2015
Next Rx: New Medicare Part D Initiative Advances Role of Medication Management in Reform Sheppard, Mullin, Richter & Hampton LLP
Feb
14
2023
FDA Issues Warning Letter to RightEye, LLC For Misbranding and Adulteration Sheppard, Mullin, Richter & Hampton LLP
Apr
10
2023
FDA To Require Demonstration of Cybersecurity Safeguards for Pre-Market Submissions of Certain Medical Devices Sheppard, Mullin, Richter & Hampton LLP
Jan
21
2024
FDA Issues Final Rule and Guidance on Direct-To-Consumer Prescription Drug Advertisements Sheppard, Mullin, Richter & Hampton LLP
Sep
8
2020
New Proposed Regulation Provides More Guidance and Some Relief on Prop 65 Warning Requirements for Heat Processed Foods and Acrylamide Sheppard, Mullin, Richter & Hampton LLP
Sep
14
2020
Trade Secret Protection & the COVID-19 Cure: Observations on Federal Policy-Making & Potential Impact on Biomedical Advances Sheppard, Mullin, Richter & Hampton LLP
Mar
9
2024
Oregon Prescription Drug Price Transparency Act in Limbo Sheppard, Mullin, Richter & Hampton LLP
Mar
11
2021
DFEH Issues Guidance to Employers Regarding Mandatory COVID-19 Vaccination Policies Sheppard, Mullin, Richter & Hampton LLP
Aug
17
2017
Scrambling After an Egg Crisis – EU Safety Guidance for Online Product Sales Sheppard, Mullin, Richter & Hampton LLP
Jun
10
2011
Superior Court's Injunction Preventing California's Cap and Trade Program Has Been Stayed...Right? Sheppard, Mullin, Richter & Hampton LLP
May
8
2021
FDA Proposes Risk-Based and Remote Inspection Strategies in New Report Sheppard, Mullin, Richter & Hampton LLP
Jun
28
2013
Recent Federal and International Developments Good for California Cap and Trade Sheppard, Mullin, Richter & Hampton LLP
Jul
12
2019
Regulating E-Cigarettes Remains “Top Priority” For FDA Sheppard, Mullin, Richter & Hampton LLP
Aug
25
2022
Healthcare Reforms Under the IRA: Expanding Access to Care Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2019
340B Program-Participating Hospitals Object to CMS’s Proposed Cuts to 340B Program Reimbursement: CMS’s Recent Information Collection Request Sheppard, Mullin, Richter & Hampton LLP
Mar
20
2023
FDA Draft Guidance Signifies Acceptance of the Term “Milk” to Describe Plant-Based Alternatives Sheppard, Mullin, Richter & Hampton LLP
Mar
25
2020
Top 10 Questions Asked By Medical Group Clients In Response To COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Jun
19
2020
Not Today Corona: EEOC Prohibits Testing Employees for Antibodies Sheppard, Mullin, Richter & Hampton LLP
Jul
2
2020
High Risk of Second Requests in the Cannabis Industry Sheppard, Mullin, Richter & Hampton LLP
Aug
10
2020
“Buy American” in the Twilight Zone: Executive Order Strengthening the U.S. Public Health Industrial Base Sheppard, Mullin, Richter & Hampton LLP
Apr
3
2024
FTC’s Campaign Against Improper Orange Book Listings Continues with Amicus Brief in Teva’s Challenge of Amneal Asthma Inhaler ANDA Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins